US2021317538A1PendingUtilityA1

Detecting pancreatic high-grade dysplasia

Assignee: MAYO FOUND MEDICAL EDUCATION & RESPriority: Apr 14, 2016Filed: Jun 14, 2021Published: Oct 14, 2021

Est. expiryApr 14, 2036(~9.7 yrs left)· nominal 20-yr term from priority

Inventors:David A. Ahlquist William R. Taylor John B. Kisiel Tracy C. Yab Douglas W. Mahoney

C12Q 2600/154C12Q 1/6886A61P 35/00C12Q 2600/112A61P 1/18

PatentIndex Score

Cited by

References

Claims

Abstract

Provided herein is technology for pancreatic high-grade dysplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of pancreatic high-grade dysplasia (IPMN-HGD, PanIN-3, or PDAC).

Claims

exact text as granted — not AI-modified

We claim: 
     
         1 . A method of screening for pancreatic high-grade dysplasia (IPMN-HGD, PanIN-3, or PDAC) in a sample obtained from a subject, the method comprising:
 a) assaying a methylation state of a marker in a sample obtained from a subject; and   b) identifying the subject as having pancreatic high-grade dysplasia (IPMN-HGD, PanIN-3, or PDAC) when the methylation state of the marker is different than a methylation state of the marker assayed in a subject that does not have pancreatic high-grade dysplasia (IPMN-HGD, PanIN-3, or PDAC), wherein the marker comprises a base in a differentially methylated region (DMR) selected from BMP3, NDRG4, ABCB1, AK055957, C13ORF18, CD1D, CLEC11A, DLX4, ELMO1, EMX1, FER1L4, FRMD4A, GRIN2D, HOXA1, LRRC4, PRKCB, SP9, ST6GAL2, ST8SIA1, TBX15, VWC2, and ZNF781.

Join the waitlist — get patent alerts

Track US2021317538A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.